CONCORD, Mass., March 13, 2018 /PRNewswire/ -- Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced that Rupert Davies, PhD, Principal Scientist, Oncology at Zymeworks is confirmed to speak at their annual Quantitative Systems Pharmacology (QSP) Day. In its second year, QSP Dayis a conference dedicated to mathematical modeling in drug research and development. It features talks from key industry and academic researchers, a poster session with awards, and networking time with peers.
This year's conference occurs Thursday, April 12, 2018 from 9:00 a.m. - 5:00 p.m. at the Samberg Conference Center, MIT Chang Building in Cambridge, MA. Dr. Davies will present "Utilizing QSP Modeling to Drive Clinical and Nonclinical Development of Zymeworks' Biparatopic Azymetric™ Platform." Applied BioMath recently announced Douglas A. Lauffenburger, PhD, Ford Professor of Biological Engineering, Chemical Engineering, and Biology, and head of the Department of Biological Engineering at Massachusetts Institute of Technology, and Haiqing Wang, PhD, Principal Scientist at Bristol-Myers Squibb will also present at QSP Day 2018.
"We are privileged to have Rupert Davies, PhD present at QSP Day," said John Burke, PhD, Co-Founder, President and CEO of Applied BioMath. "His presentation will be a great example of how QSP modeling adds value to both nonclinical and clinical drug development."
Dr. Davies currently serves as a Principal Scientist at Zymeworks, where he is responsible for the development of product candidates from the hit discovery stage through IND-enabling studies and into the clinic. Dr. Davies was part of the Zymeworks team that enabled the advancement of ZW25 into the clinic and he and the team are now focused on combining Zymework's Azymetric™ Bispecific and ZymeLink™ Antibody Drug Conjugate platforms to develop product candidates with expanded therapeutic windows. He has worked on a broad array of drugs modalities from small molecules and peptides to RNA mimics and antibodies, including four candidates that are currently being evaluated in clinical trials and two approved drugs. Prior to his current role, Dr. Davies served as Preclinical Manager at Amgen, as well as in various roles at other small start-up and medium-sized biotechs. He received his PhD in Bioengineering from the University of Utah and completed a post-doctoral fellowship in Bioengineering at the University of Washington.
All QSP Day registrants are welcome to submit posters in either the student or non-student categories. Three abstracts will be invited to give a 15 minute presentation during the conference. In addition, cash prizes will be awarded to the top three student posters, with first place receiving $1,000, second place receiving $500, and third place receiving $200.
For more information, to register, and to submit a poster, visit www.appliedbiomath.com/QSPDAY_2018.
About Applied BioMath
Founded in 2013, Applied BioMath uses mathematical modeling and simulation to provide quantitative and predictive guidance to biotechnology and pharmaceutical companies to help accelerate and de-risk drug research and development. Their Model-Aided Drug Invention (MADI) approach employs proprietary algorithms and software to support groups worldwide in decision-making from early research through clinical trials. The Applied BioMath team leverages their decades of expertise in biology, mathematical modeling and analysis, high-performance computing, and industry experience to help groups better understand their candidate, its best-in-class parameters, competitive advantages, patients, and the best path forward into and in the clinic. For more information about Applied BioMath and its services, visit www.appliedbiomath.com.
Applied BioMath and the Applied BioMath logo are registered trademarks of Applied BioMath, LLC.
SOURCE Applied BioMath, LLC